Literature DB >> 28528280

Aortic involvement in relapsing polychondritis.

Maëlle Le Besnerais1, Laurent Arnaud2, Jonathan Boutémy3, Boris Bienvenu3, Hervé Lévesque1, Zahir Amoura4, Isabelle Marie5.   

Abstract

OBJECTIVE: To assess prevalence of aortic involvement in relapsing polychondritis (RP) patients; to evaluate clinical features and long-term outcome of RP patients exhibiting aortitis, aortic ectasia and/or aneurysm.
METHODS: One hundred and seventy-two RP patients underwent aortic computed tomography (CT)-scan; they were seen in 3 medical centers.
RESULTS: Eleven patients (6.4%) had aortic involvement, occurring within a median time of 2 years after RP diagnosis. CT-scan showed isolated aortitis (n=2); the 9 other patients exhibited: aortitis and aortic aneurysm (n=2) or ectasia (n=1), isolated aortic aneurysm (n=4) or ectasia (n=2); aortic localizations were as follows: thoracic (n=6), abdominal (n=2), thoracic and abdominal (n=4) aorta. Patients exhibited: resolution (n=3) improvement (n=3), stabilization (n=4) or deterioration (n=1) of aortic localization. Five patients experienced recurrence of aortic localization; one patient died of aortic abdominal aneurysm rupture. Predictive factors of death related to aortic complications were: aortitis on CT-scan, higher median levels of erythrocyte sedimentation rate. Predictive parameters of aortic relapses were: aortitis on CT-scan and involvement of the abdominal aorta.
CONCLUSIONS: This study underlines that aortic involvement is severe in RP. Furthermore, we suggest that RP patients exhibiting poor prognostic factors, including panaortitis and higher values of ESR, may require more aggressive therapy.
Copyright © 2017 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  Aortic aneurysm; Aortic ectasia; Aortic involvement; Aortitis; Relapsing polychondritis

Mesh:

Year:  2017        PMID: 28528280     DOI: 10.1016/j.jbspin.2017.05.009

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  5 in total

Review 1.  Aortic involvement in relapsing polychondritis: case-based review.

Authors:  Mustafa Erdogan; Sinem Nihal Esatoglu; Gulen Hatemi; Vedat Hamuryudan
Journal:  Rheumatol Int       Date:  2019-11-25       Impact factor: 2.631

Review 2.  Efficacy of tocilizumab highlighted by FDG-PET/CT in a patient with relapsing polychondritis-associated aortitis.

Authors:  Ghassan Elourimi; Michael Soussan; Ursula Warzocha; Hélène Bugaud; Robin Dhôte; Sébastien Abad
Journal:  Rheumatol Int       Date:  2017-09-30       Impact factor: 2.631

3.  Relapsing polychondritis: state of the art on clinical practice guidelines.

Authors:  Simona Rednic; Laura Damian; Rosaria Talarico; Carlo Alberto Scirè; Alexander Tobias; Nathalie Costedoat-Chalumeau; David Launay; Alexis Mathian; Lisa Mattews; Cristina Ponte; Paola Toniati; Stefano Bombardieri; Charissa Frank; Matthias Schneider; Vanessa Smith; Maurizio Cutolo; Marta Mosca; Laurent Arnaud
Journal:  RMD Open       Date:  2018-10-18

4.  Relapsing polychondritis - analysis of symptoms and criteria.

Authors:  Beata Maciążek-Chyra; Magdalena Szmyrka; Marta Skoczyńska; Renata Sokolik; Joanna Lasocka; Piotr Wiland
Journal:  Reumatologia       Date:  2019-02-28

Review 5.  Mimickers of Large Vessel Giant Cell Arteritis.

Authors:  André Ramon; Hélène Greigert; Paul Ornetti; Bernard Bonnotte; Maxime Samson
Journal:  J Clin Med       Date:  2022-01-19       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.